Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of “Buy” from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) has received an average rating of “Buy” from the twenty-two research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nineteen have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $147.25.

Several research firms recently issued reports on NTLA. William Blair began coverage on Intellia Therapeutics in a report on Friday, February 18th. They set an “outperform” rating and a $144.00 target price on the stock. Piper Sandler started coverage on Intellia Therapeutics in a research report on Friday, January 7th. They set an “overweight” rating and a $171.00 price target on the stock. Chardan Capital lowered their price target on Intellia Therapeutics from $177.00 to $172.00 and set a “buy” rating on the stock in a research report on Tuesday, March 1st. Oppenheimer raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $145.00 to $150.00 in a research report on Monday, February 7th. Finally, Brookline Capital Acquisition raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a research report on Monday, March 7th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Glassman Wealth Services lifted its stake in Intellia Therapeutics by 47.7% during the third quarter. Glassman Wealth Services now owns 260 shares of the company’s stock worth $35,000 after purchasing an additional 84 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in Intellia Therapeutics by 88.1% during the third quarter. Daiwa Securities Group Inc. now owns 252 shares of the company’s stock worth $34,000 after purchasing an additional 118 shares during the last quarter. Penserra Capital Management LLC lifted its stake in Intellia Therapeutics by 8.4% during the third quarter. Penserra Capital Management LLC now owns 1,680 shares of the company’s stock worth $225,000 after purchasing an additional 130 shares during the last quarter. Arizona State Retirement System lifted its stake in Intellia Therapeutics by 0.8% during the third quarter. Arizona State Retirement System now owns 16,708 shares of the company’s stock worth $2,241,000 after purchasing an additional 139 shares during the last quarter. Finally, Blair William & Co. IL lifted its stake in Intellia Therapeutics by 1.7% during the fourth quarter. Blair William & Co. IL now owns 9,262 shares of the company’s stock worth $1,095,000 after purchasing an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 85.89% of the company’s stock.

Shares of Intellia Therapeutics stock opened at $50.03 on Friday. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -13.31 and a beta of 2.14. The stock’s 50-day moving average is $64.44 and its 200-day moving average is $94.93. Intellia Therapeutics has a one year low of $47.02 and a one year high of $202.73.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last released its earnings results on Thursday, February 24th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.18). Intellia Therapeutics had a negative return on equity of 33.61% and a negative net margin of 810.49%. The company had revenue of $12.90 million for the quarter, compared to the consensus estimate of $7.83 million. During the same quarter in the previous year, the company posted ($0.69) EPS. The business’s revenue was up 95.5% on a year-over-year basis. On average, analysts expect that Intellia Therapeutics will post -4.36 earnings per share for the current fiscal year.

About Intellia Therapeutics (Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Further Reading

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.